45 results
424B5
NTLA
Intellia Therapeutics Inc
26 Feb 24
Prospectus supplement for primary offering
7:04am
CRISPR/Cas9-based medicines;
Advance our science;
Be the best place to make therapies; and
Focus on long-term sustainability.
Our lead in vivo … ; and
Focus on long-term sustainability.
Our strategy is to advance our full-spectrum genome editing company, focused on developing and commercializing
424B5
NTLA
Intellia Therapeutics Inc
23 Feb 24
Prospectus supplement for primary offering
5:22pm
; and
Focus on long-term sustainability.
Our lead in vivo candidates, NTLA-2001 for the treatment of transthyretin (“ATTR”) amyloidosis and NTLA-2002 … ;
Advance our science;
Be the best place to make therapies; and
Focus on long-term sustainability.
Our strategy is to advance our full-spectrum genome
S-3ASR
sakcru7i69s8epp6kaul
24 Nov 23
Automatic shelf registration
9:30am
PRE 14A
tqmn3cawnk
18 Apr 23
Preliminary proxy
4:16pm
424B5
tkskst
1 Dec 22
Prospectus supplement for primary offering
5:09pm
424B5
idp8z8fd7wvtcwkv
4 Mar 22
Prospectus supplement for primary offering
5:03pm